PMID- 36330332
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221105
IS  - 2296-634X (Print)
IS  - 2296-634X (Electronic)
IS  - 2296-634X (Linking)
VI  - 10
DP  - 2022
TI  - The therapeutic effect of adipose-derived lipoaspirate cells in femoral head 
      necrosis by improving angiogenesis.
PG  - 1014789
LID - 10.3389/fcell.2022.1014789 [doi]
LID - 1014789
AB  - Femoral head necrosis (FHN), one of the most popular joint diseases in the 
      musculoskeletal system, is usually attributed to local ischemia of the femoral 
      head. Thus, regenerating the vascularization capacity and restoring the local 
      perfusion of the femoral head becomes an efficient therapeutic approach for FHN. 
      We investigated the function of autologous lipoaspirate cells (LPCs) in 
      regenerating circulation in FHN animal models and human subjects in this study. 
      We also explored the mechanisms of why LPCs show a superior effect than that of 
      the bone marrow-derived stem cells (BMSCs) in vascularization. Thirty-four FHN 
      patients were recruited for the randomized clinical trial. Harris Hip Score (HHS) 
      and digital subtraction arteriography (DSA) and interventional technique were 
      used to compare the efficacy of LPCs treatment and vehicle therapy in improving 
      femoral head circulation and hip joint function. Cellular mechanism that 
      underlies the beneficial effect of LPCs in restoring blood supply and rescuing 
      bone architecture was further explored using canine and mouse FHN animal models. 
      We found that LPCs perfusion through the medial circumflex artery will promote 
      the femoral head vascularization and bone structure significantly in both FHN 
      patients and animal models. The HHS in LPCs treated patients was significantly 
      improved relative to vehicle group. The levels of angiogenesis factor secreted by 
      LPCs such as VEGF, FGF2, VEC, TGF-beta, were significantly higher than that of 
      BMSCs. As the result, LPCs showed a better effect in promoting the tube structure 
      formation of human vascular endothelial cells (HUVEC) than that of BMSCs. 
      Moreover, LPCs contains a unique CD44(+)CD34(+)CD31(-) population. The 
      CD44(+)CD34(+)CD31(-) LPCs showed significantly higher angiogenesis potential as 
      compared to that of BMSCs. Taken together, our results show that LPCs possess a 
      superior vascularization capacity in both autonomous and paracrine manner, 
      indicating that autologous LPCs perfusion via the medial circumflex artery is an 
      effective therapy for FHN.
CI  - Copyright (c) 2022 Zhang, Zheng, Yu, Zhang, Huang, Chen, Tong and Zhen.
FAU - Zhang, Weixin
AU  - Zhang W
AD  - Department of Traditional Chinese Medical Orthopedic Surgery, Zhejiang Chinese 
      Medical University, Hangzhou, China.
AD  - Department of Orthopedic Surgery, School of Medicine, Johns Hopkins University, 
      Baltimore, MD, United States.
FAU - Zheng, Cheng
AU  - Zheng C
AD  - Zhejiang Rehabilitation Medical Center, Zhejiang, China.
FAU - Yu, Tiefeng
AU  - Yu T
AD  - Hangzhou Yingjian Bioscience & Technology Co., Ltd, Hangzhou, China.
FAU - Zhang, Houjian
AU  - Zhang H
AD  - Department of Traditional Chinese Medical Orthopedic Surgery, Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Huang, Jiaxin
AU  - Huang J
AD  - Department of Traditional Chinese Medical Orthopedic Surgery, Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Chen, Liyue
AU  - Chen L
AD  - Department of Economic and Management, University of Jinan, Shangdong, China.
FAU - Tong, Peijian
AU  - Tong P
AD  - Department of Traditional Chinese Medical Orthopedic Surgery, Zhejiang Chinese 
      Medical University, Hangzhou, China.
FAU - Zhen, Gehua
AU  - Zhen G
AD  - Department of Orthopedic Surgery, School of Medicine, Johns Hopkins University, 
      Baltimore, MD, United States.
LA  - eng
PT  - Journal Article
DEP - 20221018
PL  - Switzerland
TA  - Front Cell Dev Biol
JT  - Frontiers in cell and developmental biology
JID - 101630250
PMC - PMC9624280
OTO - NOTNLM
OT  - angiogenesis
OT  - femoral head necrosis
OT  - lipoaspirate
OT  - stem cell
OT  - theraputic
COIS- Author TY was employed by Hangzhou Yingjian Bioscience & Technology Co., Ltd. The 
      remaining authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be. construed as a potential 
      conflict of interest.
EDAT- 2022/11/05 06:00
MHDA- 2022/11/05 06:01
PMCR- 2022/01/01
CRDT- 2022/11/04 02:33
PHST- 2022/08/08 00:00 [received]
PHST- 2022/10/05 00:00 [accepted]
PHST- 2022/11/04 02:33 [entrez]
PHST- 2022/11/05 06:00 [pubmed]
PHST- 2022/11/05 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 1014789 [pii]
AID - 10.3389/fcell.2022.1014789 [doi]
PST - epublish
SO  - Front Cell Dev Biol. 2022 Oct 18;10:1014789. doi: 10.3389/fcell.2022.1014789. 
      eCollection 2022.